CN Bio Wins Most Impactful Industry Collaboration of the Year at the OBN Awards 2023 for Ongoing Research With the FDA streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
The FDA Expands Collaboration With CN Bio to Investigate Lung-on-a-chip Model for Inhaled Drug Evaluation Applications
Follows success of initial project demonstrating the advanced performance of the Company s liver-on-a-chip platform
CN Bio, a leading developer of single- and multi-organ-on-chip microphysiological systems (MPS) that improve the accuracy and efficiency of drug discovery, today announced the U.S. Food and Drug Administration (FDA) has extended their research collaboration, for a further three years. The scope of the research carried out with the FDA s Center for Drug Evaluation and Research (CDER) has now been broadened to include the exploration of CN Bio s lung-on-a-chip using the PhysioMimix MPS platform, to appraise the system s use for the evaluation of inhaled drug products and assessing additional applications for CN Bio s liver model.
CN Bio s PhysioMimix Technology Receives FDA Recognition
Represents the first co-published, peer-reviewed article between a microphysiological system provider and a regulator
CN Bio, a leading developer of single and multi organ-on-chip microphysiological systems (MPS) that improve the accuracy and efficiency of drug discovery, today announced the publication of co-authored research with the U.S. Food and Drug Administration (FDA)
1. The first co-published, peer-reviewed research paper between a commercial MPS provider and a regulator, demonstrates that data derived using CN Bio s proprietary PhysioMimix system is appropriate for use in drug safety and metabolism applications, evidencing its enhanced performance versus standard techniques. The publication substantiates the Company s position as a leader in the field with reliable and robust cutting-edge technology, ready for widespread adoption across the pharmaceutical industry.